Physician profile
Ryan D Crouch
NPI 1790724201
$2,059.93
in general payments reported to CMS, 2019-2025
42 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $270 · 2021: $64.76 · 2022: $63.85 · 2023: $144 · 2024: $440 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $269.72 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $263.89 | 2019-2022 | |
| Siemens Medical Solutions USA, INC. | $184.46 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $123.12 | 2024-2025 | Acthar |
| Pfizer INC. | $113.50 | 2019-2025 | |
| Amgen INC. | $80.46 | 2019-2024 | Otezla, Repatha, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $61.62 | 2020 | |
| Novartis Pharmaceuticals Corporation | $61.28 | 2019-2025 | |
| Lilly USA, LLC | $58.70 | 2023-2025 | Mounjaro |
| Astellas Pharma US INC | $56.65 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $54.09 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $46.83 | 2019-2025 | Trintellix |
| Abbott Laboratories | $43.21 | 2021-2024 | Freestyle Libre 3 |
| Travere Therapeutics, INC. | $37.45 | 2025 | |
| Mylan Specialty L.P. | $33.79 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Crouch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.